9786208472672 - Dynamics-based Computational Design of Anti-Cancer Drugs. 2nd Edition: An Emerging Approach to Drug Design de Fatima, Talath; Ahmed, Osman (11 resultados)

Condición: New.

Condición: New.

Taschenbuch. Condición: Neu. Dynamics-based Computational Design of Anti-Cancer Drugs. 2nd Edition | An Emerging Approach to Drug Design | Talath Fatima (u. a.) | Taschenbuch | Englisch | 2025 | LAP LAMBERT Academic Publishing | EAN 9786208472672 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu.

PAP. Condición: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

PAP. Condición: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

Taschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware 104 pp. Englisch.

Paperback. Condición: new. Paperback. Computational drug design approach has a great potential in accelerating the drug discovery process. Structure-based drug design and ligand-based drug design are the two broad classes of computational drug design. Cancer is a class of highly complex diseases involving multiple genes and multiple cross-talks between signaling networks. Cancer cells may be developed from inherited defects or acquired damages of DNA. However, many cancers are resistant to treatment, and metastasis of cancers makes the disease even more intractable. Secondary malignancies are frequently observed after cancer chemotherapy. The call for more effective cancer therapy is obligatory. Using drug-cocktails that combine multiple anti-cancer agents working in different mechanisms has been a standard treatment of cancers to overcome the drug resistance problem. More recently, design of multiple ligands (may be more easily understood as "multiple target ligands"), i.e., single agents that target multiple biomolecules in a rational manner, receives increasing attention. Some recent methodological developments on computational drug design are reviewed, and a few recent drug design efforts in cancer is summarized. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.

Condición: New. Print on Demand.

Taschenbuch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Computational drug design approach has a great potential in accelerating the drug discovery process. Structure-based drug design and ligand-based drug design are the two broad classes of computational drug design. Cancer is a class of highly complex diseases involving multiple genes and multiple cross-talks between signaling networks. Cancer cells may be developed from inherited defects or acquired damages of DNA. However, many cancers are resistant to treatment, and metastasis of cancers makes the disease even more intractable. Secondary malignancies are frequently observed after cancer chemotherapy. The call for more effective cancer therapy is obligatory. Using drug-cocktails that combine multiple anti-cancer agents working in different mechanisms has been a standard treatment of cancers to overcome the drug resistance problem. More recently, design of multiple ligands (may be more easily understood as 'multiple target ligands'), i.e., single agents that target multiple biomolecules in a rational manner, receives increasing attention. Some recent methodological developments on computational drug design are reviewed, and a few recent drug design efforts in cancer is summarized.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 104 pp. Englisch.

Taschenbuch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Computational drug design approach has a great potential in accelerating the drug discovery process. Structure-based drug design and ligand-based drug design are the two broad classes of computational drug design. Cancer is a class of highly complex diseases involving multiple genes and multiple cross-talks between signaling networks. Cancer cells may be developed from inherited defects or acquired damages of DNA. However, many cancers are resistant to treatment, and metastasis of cancers makes the disease even more intractable. Secondary malignancies are frequently observed after cancer chemotherapy. The call for more effective cancer therapy is obligatory. Using drug-cocktails that combine multiple anti-cancer agents working in different mechanisms has been a standard treatment of cancers to overcome the drug resistance problem. More recently, design of multiple ligands (may be more easily understood as 'multiple target ligands'), i.e., single agents that target multiple biomolecules in a rational manner, receives increasing attention. Some recent methodological developments on computational drug design are reviewed, and a few recent drug design efforts in cancer is summarized.

Condición: New. PRINT ON DEMAND.